Log inSign up
AAOIFI No. 21 screening

Is INDP halal?

Indaptus Therapeutics, Inc.

Halal

Indaptus Therapeutics, Inc. passed every check under AAOIFI Shariah standard No. 21: no prohibited business activity, and all three financial ratios are within limits.

Checked: 15 October 2026

Exchange

NASDAQ

Price

2.63

Day

-7.72%

Market cap

$353.1M

Industry

Biotechnology

Sector

Healthcare

What the company does

Indaptus Therapeutics is a clinical-stage immuno-oncology biotech (Decoy20 for cancer and viral infections); no commercial product or revenue.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $64.12M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $11.55M ÷ 36-month average market cap $64.12M = 18.0%

    18.0%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $353.09M.

In the lists

In the S&P 500
Not in the S&P 500
Among halal stocks
0.00% · #1042 of 1454

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyINDP's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →